{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth&page=29",
    "query": {
      "condition": "Growth",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 1656,
    "total_pages": 166,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T21:39:33.191Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00786383",
      "title": "Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "IMC-1121B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1121B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2006-02",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2013-08-19",
      "last_synced_at": "2026-10-23T21:39:33.191Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Durham, North Carolina • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00786383"
    },
    {
      "nct_id": "NCT00911170",
      "title": "PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer",
        "Colon Cancer",
        "Colorectal Cancer",
        "Fever",
        "Locally Advanced",
        "Metastatic Colorectal Cancer",
        "Neutropenia",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 847,
      "start_date": "2009-11-03",
      "completion_date": "2015-01-02",
      "has_results": true,
      "last_update_posted_date": "2017-12-29",
      "last_synced_at": "2026-10-23T21:39:33.191Z",
      "location_count": 72,
      "location_summary": "Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00911170"
    },
    {
      "nct_id": "NCT04040894",
      "title": "Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Thyroid Eye Disease",
        "Graves' Orbitopathy"
      ],
      "interventions": [
        {
          "name": "Teprotumumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-06-20",
      "last_synced_at": "2026-10-23T21:39:33.191Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Miami, Florida • Skokie, Illinois + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Plymouth Meeting",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04040894"
    },
    {
      "nct_id": "NCT00990353",
      "title": "A Model to Identify Specific Predictors of Spatial Neglect Recovery",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Spatial Neglect",
        "Hemispatial Neglect",
        "Hemineglect",
        "Unilateral Neglect",
        "Visual Spatial Neglect",
        "Sensory Neglect"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Kessler Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2009-01",
      "completion_date": "2021-10",
      "has_results": false,
      "last_update_posted_date": "2021-02-17",
      "last_synced_at": "2026-10-23T21:39:33.191Z",
      "location_count": 3,
      "location_summary": "Chester, New Jersey • Saddle Brook, New Jersey • West Orange, New Jersey",
      "locations": [
        {
          "city": "Chester",
          "state": "New Jersey"
        },
        {
          "city": "Saddle Brook",
          "state": "New Jersey"
        },
        {
          "city": "West Orange",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00990353"
    },
    {
      "nct_id": "NCT01550471",
      "title": "Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma",
        "Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo",
          "type": "DRUG"
        },
        {
          "name": "Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase",
          "type": "DRUG"
        },
        {
          "name": "QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo",
          "type": "DRUG"
        },
        {
          "name": "QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris",
          "type": "DRUG"
        },
        {
          "name": "Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase",
          "type": "DRUG"
        },
        {
          "name": "Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "West Penn Allegheny Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "6 Years to 15 Years"
      },
      "enrollment_count": 22,
      "start_date": "2012-03",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2020-11-04",
      "last_synced_at": "2026-10-23T21:39:33.191Z",
      "location_count": 2,
      "location_summary": "Green Tree, Pennsylvania • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Green Tree",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01550471"
    },
    {
      "nct_id": "NCT00833222",
      "title": "Neuroendocrine Mechanisms of Growth and Body Composition in Preterm and Term Infants",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Premature Birth"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "31 Weeks",
        "maximum_age": "42 Weeks",
        "sex": "ALL",
        "summary": "31 Weeks to 42 Weeks"
      },
      "enrollment_count": 72,
      "start_date": "2008-01",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2017-12-26",
      "last_synced_at": "2026-10-23T21:39:33.191Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00833222"
    },
    {
      "nct_id": "NCT01520077",
      "title": "Vytorin in the Treatment of Alopecia Areata",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alopecia Areata"
      ],
      "interventions": [
        {
          "name": "vytorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2011-07",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2015-03-17",
      "last_synced_at": "2026-10-23T21:39:33.191Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01520077"
    },
    {
      "nct_id": "NCT03041701",
      "title": "Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Rhabdomyosarcoma",
        "Rhabdomyosarcoma, Alveolar",
        "Rhabdomyosarcoma, Embryonal"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Ganitumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2017-07-07",
      "completion_date": "2021-10-16",
      "has_results": true,
      "last_update_posted_date": "2022-04-14",
      "last_synced_at": "2026-10-23T21:39:33.191Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Bethesda, Maryland",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03041701"
    },
    {
      "nct_id": "NCT03685331",
      "title": "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Locally Advanced Breast Cancer",
        "Advanced Breast Cancer",
        "BRCA2 Mutation",
        "BRCA1 Mutation"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2020-10-15",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-23T21:39:33.191Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03685331"
    },
    {
      "nct_id": "NCT06901531",
      "title": "A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer",
        "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer",
        "Metastatic Gastric Adenocarcinoma or Cancer",
        "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "zolbetuximab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Folinic acid (leucovorin or local equivalent)",
          "type": "DRUG"
        },
        {
          "name": "5-fluorouracil (5-FU)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2025-05-22",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-23T21:39:33.191Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06901531"
    }
  ]
}